Oral anticoagulation: improving the risk-benefit ratio

Area of Science:

• Pharmacology
• Cardiology
• Hematology

Background:

• Warfarin has been a cornerstone anticoagulant for four decades, primarily for thromboembolic disorders.
• Advances in monitoring, including the international normalized ratio (INR), have improved warfarin management.
• Evolving clinical guidelines suggest expanded use of warfarin for various cardiovascular and thromboembolic conditions.

Purpose of the Study:

• To review the current status of warfarin therapy in managing thromboembolic disorders.
• To highlight challenges and strategies in optimizing warfarin's risk-benefit ratio.
• To discuss the implications of new clinical information on warfarin's expanded therapeutic applications.

Main Methods:

• Review of clinical guidelines and scientific literature on warfarin therapy.
• Analysis of advances in anticoagulant monitoring and therapeutic range adjustments.
• Discussion of strategies for enhancing warfarin effectiveness and safety.

Main Results:

• The international normalized ratio (INR) has standardized warfarin monitoring, addressing thromboplastin variability.
• Recommended INR ranges have shifted towards lower intensity, influencing treatment protocols.
• New evidence supports broader use of warfarin in atrial fibrillation, prosthetic heart valves, and post-myocardial infarction care.

Conclusions:

• Optimal warfarin management remains complex due to its narrow therapeutic index.
• Strategies focusing on improving warfarin's effectiveness and safety profile are crucial for better patient outcomes.
• Continued research and refined clinical practices are essential for maximizing the benefits of warfarin therapy.